

Plenary sessions

PLE01-01	Spectral FC in the clinical lab	Cristina Teodosio (Leiden, NL)
PLE02-01	Clinical application of computational flow cytometry	Carolien Duetz (Amsterdam, NL)
PLE03-01	MRD as a surrogate end point in clinical studies	Monika Brüggemann (Kiel, DE)
PLE04-01	Case presentation: Epichaperome abundance as a novel assessment to guide therapy	Monica Guzman (New York, USA)
PLE04-02	Case presentation: Diagnostic challenges in T-lymphoblastic leukemia/lymphoma	Sindhu Cherian (Washington, USA)
PLE05-01	Immune monitoring of personalized cancer vaccines	Evelyna Derhovanessian (Mainz, DE)
PLE06-01	Case presentation: Primary immunodeficiency cases	Martín Pérez y Andrés (Salamanca, ES)
PLE06-02	Case presentation: A misleading flow cytometric finding in the diagnostic process of lymphoma	Arianna Gatti (Milan, IT)

Parallel sessions (education streams)

PAR01 Hematology-Oncology - Multiple Myeloma

PAR01-01	Monitoring response to therapy by flow in myeloma based on circulating tumor plasma cells and immune cells	Alberto Orfao (Salamanca, ES)
PAR01-02	MRD driven clinical trials in MM	Valdas Peceliunas (Vilnius, LT)

PAR02 Data Analysis - Introduction to data representation

PAR02-01	General Principles	Yvan Saeys (Ghent, BE)
PAR02-02	Visualization - Back to basics	Samuel Granjeaud (Marseille, FR)

PAR03 Immunology - The tumor microenvironment

PAR03-01	The immune tumor microenvironment in the context of checkpoint inhibitor treatment	Barbara Seliger (Halle, DE)
PAR03-02	Multidimensional analysis of Tumor-specific non-conventional T cells	Gennaro De Libero (Basel, CH)

PAR04 Antigen-Specific Immunity - T-cells/infectious antigens

PAR04-01	Priming of human virus or tumor specific naïve T cells	Victor Appay (Paris, FR)
PAR04-02	Coronavirus-specific CD4+ T cells: questions around protective immunity and immunopathology	Lucie Loyal (Berlin, DE)

PAR05 Hematology-Oncology - CAR-T

PAR05-01	News and Views on CAR-T Cell Therapy	Michael Hudecek (Würzburg, DE)
PAR05-02	Lab monitoring of CAR-T	Kathleen Gallagher (Boston, USA)

PAR06 Data Analysis - The Curse Of Dimensionality

PAR06-01	Dimensionality Reduction – Introduction	Karel Fišer (Prague, CZ)
PAR06-02	High dimensional cluster analysis	Yvan Saeys (Ghent, BE)

PAR07 Immunology - Infectious diseases and vaccination

PAR07-01	Next generation vaccines for infectious diseases	Rita Carsetti (Rome, IT)
PAR07-02	Flow cytometric profiling of immune responses to vaccination	Annalisa Ciabattini (Siena, IT)

PAR08 Antigen-Specific Immunity - CAR-T-cells/technology

PAR08-01	Nanobody-based dual-specific chimeric antigen T-cell receptors	Bart Vandekerckhove (Ghent, BE)
PAR08-02	Immunogenicity of CAR/TCR-T cells	Cor Lamers (Rotterdam, NL)

PAR09 Hematology-Oncology - Myelodysplastic Syndromes

PAR09-01	Evolution of diagnostics in MDS: From morphology to genetics	Wolfgang Kern (Munich, DE)
PAR09-02	Flow-cytometric approach to MDS	Uta Oelschaegele (Dresden, DE)

PAR10 Data Analysis - High-dimensional data analysis and management

PAR10-01	Democratizing computational analysis in cytometry	Josef Spidlen (Ashland, USA)
PAR10-02	Navigate safely through a sea of data: Smart information management	Nicole Weit (Krefeld, DE)

PAR11 Immunology - Cancer immunotherapy and follow-up

PAR11-01	Could peripheral T cells predict treatment response in solid tumors during immunotherapy era?	Skaiste Tulyte (Vilnius, LT)
PAR11-02	Circulating and tumor-infiltrating dendritic cells in patients with different types of cancer	Silvia Della Bella (Milan, IT)

PAR12 Antigen-Specific Immunity - Neuroscience/ageing

PAR12-01	Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis	Marvin van Luijn (Rotterdam, NL)
PAR12-02	Characterization of Brain infiltrating T-cells	Jörg Hamann (Amsterdam, NL)

PAR13 Hematology-Oncology - MRD in hematological malignancies

PAR13-01	Tailoring therapies to target leukemic stem cells	Monica Guzman (New York, USA)
PAR13-02	Update on MRD-driven strategies in AML	Maria Del Principe (Rome, IT)

PAR14 Data Analysis - Large cohort interrogation

PAR14-01	How do I prepare myself and my data for a cohort analysis?	Tomas Kalina (Prague, CZ)
PAR14-02	Large cohorts interrogation	Cirino Botta (Cosenza, IT)

PAR15 Immunology - Round table discussion: Deep Phenotyping of immune cells: Which is the best strategy?

PAR15-01	Multiparametric flow cytometry	Mathias Streitz (Berlin, DE)
PAR15-02	Immunophenotyping of Cancer Microenvironments by Imaging Mass Cytometry	Noel de Miranda (Leiden, NL)
PAR15-03	Spectral flow cytometry	Cristina Teodosio (Leiden, NL)

PAR16	Antigen-specific immunity in skin and mucosal surfaces	
PAR16-01	Intestinal anti-fungal Th17 drives allergic airway inflammation in humans	Petra Bacher (Kiel, DE)
PAR16-02	Antigen-specific T lymphocytes in Psoriasis lesions	Tiago Reis Matos (Amsterdam, NL)
PAR17	Hematology-Oncology - Game of clones in PNH and BMF	
PAR17-01	Immunological perturbations in BMF	Shahram Kordasti (London, NL)
PAR17-02	Recent Advances in PNH Testing	Andrea Illingworth (Bangor, USA)
PAR18	On the new EU-IVD Regulation	
PAR18-01	The new regulation on in vitro diagnostics (IVDR): key insights for diagnostic laboratories	Bart Lubbers (Leiden, NL)
PAR18-02	Individual and collective action in preparation for the IVDR	Jacques van Dongen (Leiden, NL)
PAR19	Immunology - Immunodeficiency and autoimmunity	
PAR19-01	Phenotyping profiles for diagnosing immunodeficiencies	Martín Pérez y Andrés (Salamanca, ES)
PAR19-02	Monogenic autoimmunity	Kai Kisand (Tartu, EE)
PAR20	Antigen-Specific Immunity - T-cell differentiation and Immunosenescence	
PAR20-01	CD28 null T-cells in autoimmune disease	Niels Hellings (Hasselt, BE)
PAR20-02	CD28null T-cells and vascular disease	Florian Kern (Brighton, UK)

Best Abstract Presentations

BAP01	Best Abstract Presentations - Hematology-Oncology	
BAP01-01	Immunologic Characterization of Coronavirus Disease 2019 (COVID-19) Patients with Hematological Cancer: Biologic and Clinical Significance	Catarina Maia (Pamplona, ES)
BAP01-02	Flow cytometric detection of Ki-67 proliferative and Bcl-2 anti-apoptotic indices in MDS and AML, and their potential clinical impact	Stefan Mestrum (Maastricht, NL)
BAP02	Best Abstract Presentations - Advances in Cytometry & Data analysis	
BAP02-01	A bioinformatic approach to improve acute myeloid leukemia prognosis	Artuur Couckuyt (Ghent, BE)
BAP02-02	Validation of CLL ERIC MRD Flow Cytometry panel in a CAP/CLIA-compliant model	Marc Brugarolas (Geneva, CH)
BAP03	Best Abstract Presentations - Immunology	
BAP03-01	Immunological biomarkers of fatal COVID-19: a study of 513 patients	Esperanza Martín-Sánchez (Pamplona, ES)
BAP04	Best Abstract Presentations - Immunology	
BAP04-01	Molecular biomarkers of murine tumor immunogenicity and prediction of response to dendritic cell vaccines and anti-PD-1 treatment	Karolina Zilionyte (Vilnius, LT)
BAP04-02	MDSC are a new target to improve graft-versus-leukemia activity of NK cells in haplo-HSC transplantation	Nicola Tumino (Rome, IT)
BAP05	Best Abstract Presentations - Hematology-Oncology	
BAP05-01	Minimal Residual Disease (MRD) in Multiple Myeloma (MM) patients undergoing Daratumumab therapy	Paola Pacelli (Siena, IT)
BAP05-02	Improvement of the immunophenotypic abnormalities after therapy with 5-Azacitidine correlates with best clinical response in MDS patients	Dolores Subirá (Guadalajara, ES)
BAP06	Best Abstract Presentations - Advances in Cytometry & Data analysis	
BAP06-01	Expression of the pathogenic HERV-W envelope in T lymphocytes of COVID-19 patients	Antonella Minutolo (Rome, IT)
BAP06-02	Guidance for Validation of laboratory developed flow cytometric tests in medical laboratories	Ulrich Sack (Leipzig, DE)
BAP07	Best Abstract Presentations - Immunology	
BAP07-01	Dendritic Cell-monocyte-Th1-axis cells combined with IL6 and IL10 levels provide an alarming immunological-signature for early prediction of severe COVID-19	Prashant Thembare (Navi Mumbai, IN)
BAP07-02	Pneumococcal Serotype-specific B-cellular Response in pediatric Nephrotic Syndrome under Cyclosporin-A: Implementation of a novel antigen-specific B-cell detection method	Marianna Tzanoudaki (Athens, GR)
BAP08	Best Abstract Presentations - Immunology	
BAP08-01	Alterations of lymphocyte immunophenotype as possible predictors of susceptibility to infections in patients of Idic-15 syndrome, a neurological rare disease	José-Enrique O'Connor (Valencia, ES)
BAP08-02	The rise and fall of monocyte CD169 expression as a biomarker of SARS-CoV2 infection and recovery	Arianna Gatti (Legnano, Milan, IT)
BAP09	Best Abstract Presentations - Hematology-Oncology	
BAP09-01	Non-valvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures	Luisa Weis (Dublin, IE)
BAP09-02	Implementation of the TCRβ1 study in clinical workflow	Dolores Subirá (Guadalajara, ES)
BAP10	Best Abstract Presentations - Advances in Cytometry & Data analysis	
BAP10-01	Clinical relevance of LOD/LOQ - based flow cytometry approach for MRD assessment in AML: post-hoc analysis of GIMEMA AML1310 trial	Raffaele Palmieri (Rome, IT)
BAP10-02	Erythrocyte Lysing Solutions Have a Detrimental Effect in Flow Cytometric Dendritic Cell Detection	Laura G. Rico (Badalona, ES)
BAP11	Best Abstract Presentations - Immunology	
BAP11-01	Prognostic value of the CD8+: B-cells ratio in COVID-19 severity and outcome	Maria Detsika (Pefki, GR)
BAP11-02	Peripheral lymphocytic subsets of COVID-19 patients upon admission to a reference tertiary hospital	Evdoxia Gounari (GR)
BAP12	Best Abstract Presentations - Immunology	
BAP12-01	Lymphocyte subset count and outcome of COVID-19 patients admitted to a highly complex hospital in southern Brazil	Ana Paula de Azambuja (Curitiba, BR)
BAP12-02	Immunomodulatory effect of long chain polyunsaturated fatty acids (LCPUFA) in association with IL-10 -1082 A/G in children with food allergy	Anna Taparkou (Thessaloniki, GR)